Prospective registration of all newly diagnosed patients (children, adolescents and young adults) with rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcomas and tumours as part of a non-interventional study/application observation (NIS) with the following objectives:
1) Data collection from patients who receive routine examinations and standard treatment in the participating centres outside of clinical studies. Off-label medications are not documented in this registry/NIS.
- Collection of information on the frequency of different types of soft tissue tumours as rare diseases
- Evaluation of the quality of treatment using data collection and data verification with the help of the registry and the CWS reference centres.
- Prospective collection of information on epidemiological, diagnostic, molecular, clinical and treatment data from patients with WTS and other soft tissue tumours to determine whether there is a correlation
between treatment outcomes and specific characteristics
- Collection of survival data, including long-term follow-up, quality of life
2) Observation of the use of approved drugs WITHIN the approved indications, population (NO off-label use):
- RMS treated with standard therapies (only if not included in the FaR-RMS study). No off-label use
- NTRK-positive NRSTS treated with NTRK inhibitors
